Information Provided By: 
Fly News Breaks for September 19, 2019
MYL, PFE
Sep 19, 2019 | 06:47 EDT
JPMorgan analyst Chris Schott lowered his price target for Pfizer (PFE) to $37 from $46 and keeps a Neutral rating on the shares. While the Mylan (MYL)/Upjohn transaction creates a smaller, innovation-driven biopharma business and increases the company's near-term growth prospects, Pfizer's multiple is ahead of itself with the remaining company trading near the top end of the major pharma valuation range, Schott tells investors in a research note. He points out that Pfizer is facing "another major patent cycle" post 2025.
News For PFE;MYL From the Last 2 Days
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
